vs
Side-by-side financial comparison of CaliberCos Inc. (CWD) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $2.2M, roughly 1.8× Instil Bio, Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -365.3%, a 177.0% gap on every dollar of revenue. On growth, Instil Bio, Inc. posted the faster year-over-year revenue change (-19.2% vs -52.5%).
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
CWD vs TIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $2.2M |
| Net Profit | $-7.7M | $-8.2M |
| Gross Margin | — | — |
| Operating Margin | -196.6% | -426.3% |
| Net Margin | -188.3% | -365.3% |
| Revenue YoY | -52.5% | -19.2% |
| Net Profit YoY | 32.2% | 31.1% |
| EPS (diluted) | $1.95 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | $2.2M | ||
| Q3 25 | $3.6M | $2.2M | ||
| Q2 25 | $5.1M | $2.2M | ||
| Q1 25 | $7.3M | $2.2M | ||
| Q4 24 | $8.7M | $2.8M | ||
| Q3 24 | $11.3M | $1.5M | ||
| Q2 24 | $8.2M | $0 | ||
| Q1 24 | $23.0M | $0 |
| Q4 25 | $-7.7M | $-8.2M | ||
| Q3 25 | $-4.4M | $-13.6M | ||
| Q2 25 | $-5.3M | $-21.4M | ||
| Q1 25 | $-4.4M | $-28.2M | ||
| Q4 24 | $-11.4M | $-11.9M | ||
| Q3 24 | $146.0K | $-23.0M | ||
| Q2 24 | $-4.7M | $-14.9M | ||
| Q1 24 | $-3.8M | $-24.3M |
| Q4 25 | -196.6% | -426.3% | ||
| Q3 25 | -129.6% | -670.0% | ||
| Q2 25 | -112.4% | -1045.5% | ||
| Q1 25 | -62.7% | -1363.2% | ||
| Q4 24 | -236.8% | -426.1% | ||
| Q3 24 | 0.0% | -1582.8% | ||
| Q2 24 | -65.0% | — | ||
| Q1 24 | -22.9% | — |
| Q4 25 | -188.3% | -365.3% | ||
| Q3 25 | -120.2% | -606.0% | ||
| Q2 25 | -104.5% | -954.2% | ||
| Q1 25 | -60.7% | -1257.8% | ||
| Q4 24 | -247.6% | -428.8% | ||
| Q3 24 | 1.3% | -1541.9% | ||
| Q2 24 | -57.8% | — | ||
| Q1 24 | -16.6% | — |
| Q4 25 | $1.95 | $-1.13 | ||
| Q3 25 | $-1.65 | $-2.01 | ||
| Q2 25 | $-4.15 | $-3.24 | ||
| Q1 25 | $-3.85 | $-4.32 | ||
| Q4 24 | $-10.15 | $-1.82 | ||
| Q3 24 | $0.12 | $-3.54 | ||
| Q2 24 | $-4.34 | $-2.29 | ||
| Q1 24 | $-3.53 | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3M | $113.9M |
| Total Assets | $135.4M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $6.6M | ||
| Q3 25 | $10.9M | $5.8M | ||
| Q2 25 | $683.0K | $7.7M | ||
| Q1 25 | $1.6M | $15.4M | ||
| Q4 24 | $2.3M | $8.8M | ||
| Q3 24 | $1.6M | $6.7M | ||
| Q2 24 | $1.8M | $6.8M | ||
| Q1 24 | $2.1M | $5.5M |
| Q4 25 | $1.3M | $113.9M | ||
| Q3 25 | $4.2M | $120.4M | ||
| Q2 25 | $-19.9M | $131.7M | ||
| Q1 25 | $-15.8M | $144.9M | ||
| Q4 24 | $-12.6M | $169.4M | ||
| Q3 24 | $-3.8M | $176.3M | ||
| Q2 24 | $-4.7M | $195.0M | ||
| Q1 24 | $-745.0K | $205.8M |
| Q4 25 | $135.4M | $203.5M | ||
| Q3 25 | $82.6M | $211.8M | ||
| Q2 25 | $59.3M | $231.0M | ||
| Q1 25 | $103.6M | $237.4M | ||
| Q4 24 | $105.5M | $263.6M | ||
| Q3 24 | $158.6M | $272.6M | ||
| Q2 24 | $195.2M | $294.3M | ||
| Q1 24 | $201.5M | $306.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | $-7.1M | ||
| Q3 25 | $-4.6M | $-10.6M | ||
| Q2 25 | $-1.2M | $-14.8M | ||
| Q1 25 | $-1.7M | $-4.2M | ||
| Q4 24 | $555.0K | $-10.6M | ||
| Q3 24 | $-74.0K | $-20.1M | ||
| Q2 24 | $1.4M | $-10.6M | ||
| Q1 24 | $-1.5M | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
